Globus Medical jumps 3% as analysts lift estimates ahead of May earnings
Globus Medical shares rose about 3% to $95.75 as investors bid up the stock ahead of its next earnings report expected on May 14, 2026. Recent analyst estimate revisions and a Zacks Rank upgrade to #1 (Strong Buy) helped drive the move as attention returns to GMED’s raised 2026 EPS outlook of $4.40–$4.50.
1. What’s moving the stock today
Globus Medical (GMED) is trading higher today as the market prices in a more optimistic earnings setup into the company’s next report, which is widely expected around May 14, 2026. In the past week, a visible catalyst has been the uptick in earnings estimate momentum and ranking upgrades tied to those revisions, which tends to pull in short-term momentum and quant-driven buying in addition to discretionary investors. (zacks.com)
2. The fundamental backdrop investors are re-rating
The re-acceleration narrative traces back to the company’s most recent full-year update, where Globus Medical reaffirmed 2026 revenue guidance of $3.18–$3.22 billion while lifting its non-GAAP diluted EPS outlook to $4.40–$4.50. That combination—steady top-line expectations with a higher profit outlook—has kept focus on margin expansion and operating leverage as the core driver of multiple expansion. (globenewswire.com)
3. What to watch next
With earnings approaching, traders will be focused on whether management reiterates or advances the higher EPS framework and whether procedure demand and enabling-technology growth remain strong enough to support the margin story. Any commentary on integration benefits and the cadence of revenue recognition will also matter for near-term sentiment and expectations-setting into the second half of 2026. (globenewswire.com)